Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Bristol-Myers Squibb Co., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Short-term debt obligations	2,046)	3,119)	4,264)	4,948)	2,340)
Accounts payable	3,602)	3,259)	3,040)	2,949)	2,713)
Rebates and discounts	9,021)	7,680)	6,702)	6,399)	5,688)
Income taxes	1,514)	1,371)	942)	754)	647)
Employee compensation and benefits	1,694)	1,291)	1,425)	1,375)	1,412)
Research and development	1,366)	1,257)	1,359)	1,373)	1,423)
Dividends	1,258)	1,213)	1,196)	1,186)	1,129)
Interest	572)	349)	321)	378)	434)
Royalties	477)	465)	431)	410)	461)
Current operating lease liabilities	181)	162)	136)	169)	164)
Contingent value rights	—)	—)	—)	—)	515)
Other	2,043)	2,096)	2,074)	1,927)	2,154)
Other current liabilities	18,126)	15,884)	14,586)	13,971)	14,027)
Current liabilities	23,774)	22,262)	21,890)	21,868)	19,080)
Deferred income taxes	369)	338)	2,166)	4,501)	5,407)
Long-term debt, excluding current portion	47,603)	36,653)	35,056)	39,605)	48,336)
Income taxes	1,491)	3,288)	3,992)	4,835)	5,017)
Pension and postretirement	400)	480)	402)	654)	899)
Non-current operating lease liabilities	1,370)	1,530)	1,261)	874)	833)
Deferred income	230)	300)	283)	326)	357)
Deferred compensation	456)	427)	349)	427)	344)
Contingent value rights	256)	—)	—)	—)	—)
Other	266)	396)	303)	218)	326)
Other non-current liabilities	4,469)	6,421)	6,590)	7,334)	7,776)
Non-current liabilities	52,441)	43,412)	43,812)	51,440)	61,519)
Total liabilities	76,215)	65,674)	65,702)	73,308)	80,599)
Preferred stock, $2 convertible series, par value $1 per share	—)	—)	—)	—)	—)
Common stock, par value of $0.10 per share	292)	292)	292)	292)	292)
Capital in excess of par value of stock	46,024)	45,684)	45,165)	44,361)	44,325)
Accumulated other comprehensive loss	(1,238)	(1,546)	(1,281)	(1,268)	(1,839)
Retained earnings	14,912)	28,766)	25,503)	23,820)	21,281)
Cost of treasury stock	(43,655)	(43,766)	(38,618)	(31,259)	(26,237)
Total BMS shareholders’ equity	16,335)	29,430)	31,061)	35,946)	37,822)
Noncontrolling interest	53)	55)	57)	60)	60)
Total equity	16,388)	29,485)	31,118)	36,006)	37,882)
Total liabilities and equity	92,603)	95,159)	96,820)	109,314)	118,481)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Bristol-Myers Squibb Co. current liabilities increased from 2022 to 2023 and from 2023 to 2024.
Non-current liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Bristol-Myers Squibb Co. non-current liabilities decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Bristol-Myers Squibb Co. total liabilities decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Total BMS shareholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Bristol-Myers Squibb Co. total BMS shareholders’ equity decreased from 2022 to 2023 and from 2023 to 2024.

Bristol-Myers Squibb Co. (NYSE:BMY)

Balance Sheet: Liabilities and Stockholders’ Equity